Severe Combined Immunodeficiency with Absence of T and B Cells

An inherited, severe immunodeficiency disorder characterized by abnormalities in the development and function of T and B cell immunity. The peripheral T and B lymphocytes are absent or in very low counts.


Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 7th ed.)


Stage IVC Laryngeal Verrucous Carcinoma AJCC v7


Stage IVB Laryngeal Verrucous Carcinoma AJCC v7

Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0).  T4b: Supraglottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Glottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Subglottis: Very advanced local disease.  Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVA Laryngeal Verrucous Carcinoma AJCC v7

Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); T4a: Supraglottis: Moderately advanced local disease.  Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). Subglottis: Moderately advanced local disease.  Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus).  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7

Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7

Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0).  T4b: Tumor with very advanced local disease.  Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  N3: Metastasis in a lymph node more than 6 cm in greatest dimension.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7

Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Tumor with moderately advanced local disease.  Tumor invades the thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue.  Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.  T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or less in greatest dimension.  T2: Tumor invades more than one subsite of the hypopharynx or an adjacent site, or measures more than 2 cm but not more than 4 cm in greatest diameter without fixation of hemilarynx.  T3: Tumor measuring more than 4 cm in greatest dimension or tumor with fixation of hemilarynx or extension to esophagus.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis.  (AJCC 7th ed.)


Stage III Thyroid Gland Medullary Carcinoma AJCC v7

Stage III includes: (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Thyroid Gland Medullary Carcinoma AJCC v7

Stage IV includes: IVA (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0); IVB (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)


Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)


Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

Stage IVB includes: Any T, N3, M0.  N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7

Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


Exposure to radiation

Exposure to radioactive materials or ionizing radiation, whether by external irradiation, contact or contamination with radioactive material, or incorporation of radioactive materials, as in the case of certain diagnostic procedures.


Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7


Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7

Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Tumor with moderately advanced local disease.  Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.  Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx. T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis.  (AJCC 7th ed.)


Stage II Renal Pelvis Cancer AJCC v7

Stage II includes: T2, N0, M0.  T2: Tumor invades muscularis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage III Renal Pelvis Cancer AJCC v7

Stage III includes: T3, N0, M0.  T3: Tumor invades beyond muscularis into peripelvic fat or the renal parenchyma.  N0: No lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IV Renal Pelvis Cancer AJCC v7

Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, N3, M0); (Any T, Any N, M1).  T4: Tumor invades adjacent organs, or through the kidney into perinephric fat.  N0: No regional lymph node metastasis.  N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension.  N2: Metastasis in a single lymph node, more than 2 cm but not more than 5cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension.  N3: Metastasis in a lymph node, more than 5 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Stage II Ureter Cancer AJCC v7

Stage II includes: T2, N0, M0.  T2: Tumor invades the muscularis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Ureter Cancer AJCC v7

Stage III includes: T3, N0, M0. T3: Tumor invades beyond muscularis into periureteric fat.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IV Ureter Cancer AJCC v7

Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, N3, M0); (Any T, Any N, M1).  T4: Tumor invades adjacent organs, or through the kidney into the perinephric fat.  N0: No regional lymph node metastasis.  N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension.  N2: Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, none more than 5 cm in greatest dimension.  N3: Metastasis in a lymph node, more than 5 cm in greatest dimension.  M0: No distant metastasis.  N1: Distant metastasis.  (AJCC 7th ed.)


Bladder transitional cell carcinoma stage I

Stage I includes: T1, N0, M0.  T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage II Urethral Cancer AJCC v7

Stage II includes: T2, N0, M0.  T2: Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Urethral Cancer AJCC v7

Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0), (T3, N1, M0).  T1: Tumor invades subepithelial connective tissue.  T2: Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle.  T3: Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck.  N1: Metastasis in a single lymph node 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Urethral Cancer AJCC v7

Stage IV includes: (T4, N0, M0); (T4, N1, M0); (Any T, N2, M0), (Any T, Any N, M1).  T4: Tumor invades other adjacent organs.  N0: No regional lymph node metastasis.  N1: Metastasis in a single lymph node 2 cm or less in greatest dimension.  N2: Metastasis in a single lymph node more than 2 cm in greatest dimension, or in multiple lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)


Childhood Central Nervous System Teratoma

A mature or immature teratoma affecting the central nervous system and occurring in children.


central nervous system endodermal sinus tumor

A yolk sac tumor that arises from the central nervous system and occurs during childhood.


thalamic cancer

A cancer involving a dorsal plus ventral thalamus.


Ventricular Premature Complex by ECG Finding

biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

An electrocardiographic finding of an ectopic impulse originating in the ventricles. The QRS morphology of these complexes is different from those of supraventricular origin. The QRS duration is often longer and the RR interval preceding the complexes is usually shorter than that of supraventricular beats. (CDISC)


Central Nervous System Carcinoma

A malignant tumor arising in the epithelial cells of the brain or spinal cord.


Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)


Valvular stenosis

Narrowing of the opening of one or more of the four valves of the heart.


Periodontal Pocket

An abnormal deepening of a gingival sulcus associated with destruction of the supporting periodontal tissue.


Stage IIIA Ovarian Cancer AJCC v6 and v7

Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIB Ovarian Cancer AJCC v6 and v7

Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIC Ovarian Cancer

Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IA Fallopian Tube Cancer AJCC v6 and v7

Stage IA includes: T1a, N0, M0. T1a: Tumor limited to one tube, without penetrating the serosal surface; no ascites.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IB Fallopian Tube Cancer AJCC v6 and v7

Stage IB includes: T1b, N0, M0.  T1b: Tumor limited to both tubes, without penetrating the serosal surface; no ascites.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IC Fallopian Tube Cancer AJCC v6 and v7

Stage IC includes: T1c, N0, M0.  T1c: Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage IIA Fallopian Tube Cancer AJCC v6 and v7

Stage IIA includes: T2a, N0, M0.  T2a: Extension and/or metastasis to the uterus and/or ovaries.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage IIIA Fallopian Tube Cancer AJCC v7

Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal metastasis outside the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIB Fallopian Tube Cancer AJCC v7

Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIIC Fallopian Tube Cancer AJCC v7

Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0).  T3c: Peritoneal metastasis outside the pelvis and more than 2 cm in diameter.  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIC Fallopian Tube Cancer AJCC v6 and v7

Stage IIC includes: T2c, N0, M0.  T2c: Pelvic extension with malignant cells in ascites or peritoneal washings.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage IIB Fallopian Tube Cancer AJCC v6 and v7

Stage IIB includes: T2b, N0, M0.  T2b: Extension to other pelvic structures.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Growth Hormone Secretion Abnormality

An abnormal production of growth hormone.


Undifferentiated Fallopian Tube Carcinoma

An invasive carcinoma arising from the fallopian tube. It is characterized by the presence of a diffuse malignant infiltrate that is composed of epithelial cells without evidence of glandular or squamous differentiation.


Stage IIC Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIC includes: T2c, N0, M0. T2c: Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washing. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIB Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIB includes: T2b N0, M0. T2b: Extension and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIA Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIA includes: T2a, N0, M0. T2a: Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIA Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIIA includes: T3a, N0, M0. T3a: Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIB Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIIB includes: T3b, N0, M0. T3b: Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIC Ovarian Germ Cell Tumor AJCC v6 and v7

Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal metastasis beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IA Uterine Corpus Cancer AJCC v7

Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IB Uterine Corpus Cancer AJCC v7

Stage IB includes: T1b, N0, M0.  T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IIIA Uterine Corpus Cancer AJCC v7

Stage IIIA includes: T3a, N0, M0.  T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IIIB Uterine Corpus Cancer AJCC v7

Stage IIIB includes: T3b, N0, M0.  T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IIIC Uterine Corpus Cancer AJCC v7

Stage IIIC includes: IIIC1 (T1-T3, N1, M0); IIIC2 (T1-T3, N2, M0). T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  Endocervical glandular involvement only should be considered as Stage I and not as Stage II. T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. N1: Regional lymph node metastasis to pelvic lymph nodes. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IVA Uterine Corpus Cancer AJCC v7

Stage IVA includes: T4, Any N, M0. T4: Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4).  M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IVB Uterine Corpus Cancer AJCC v7

Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, or lung, liver, or bone.  It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa). This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)


Stage IA Cervical Cancer AJCC v6 and v7

Stage IA includes: IA (T1a, N0, M0); IA1 (T1a1, N0, M0); IA2 (T1a2, N0, M0).  T1a: Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. T1a1: Measured stromal invasion 3.0 mm or less in depth and 7.0 or less horizontal spread.  T1a2: Measured stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IB Cervical Cancer AJCC v6 and v7

Stage IB includes: IB (T1b, N0, M0); IB1(T1b1, N0, M0); IB2 (T1b2, N0, M0). T1b: Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. T1b1: Clinically visible lesion 4.0 cm or less in greatest dimension. T1b2: Clinically visible lesion more than 4.0 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IB2 Cervical Cancer

Stage IB2 includes: T1b2, N0, M0.  T1b2: Clinically visible lesion more than 4.0 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIB Cervical Cancer AJCC v6 and v7

Stage IIB includes: T2b, N0, M0.  T2b: Tumor with parametrial invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIB Cervical Cancer AJCC v6 and v7

Stage IIIB includes: (T3b, Any N, M0); (T1-3, N1, M0).  T3: Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or non-functioning kidney. T3b: Tumor extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IIIA Cervical Cancer AJCC v6 and v7

Stage IIIA includes: T3a, N0, M0.  T3a: Tumor involves lower third of vagina, no extension to pelvic wall.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IVA Cervical Cancer AJCC v6 and v7

Stage IVA includes: T4, Any N, M0). T4: Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IVB Cervical Cancer AJCC v6 and v7

Stage IVB includes: Any T, Any N, MI. M1: Distant metastasis. (AJCC 6th and 7th eds.)


Metastatic Carcinoma to the Uterine Cervix

A carcinoma that has spread to the cervix from another anatomic site.


cervical clear cell adenocarcinoma

A rare morphologic variant of cervical adenocarcinoma composed of clear and hobnail cells. It is associated with in utero exposure to diethylstilbestrol (DES).


Testicular Mixed Choriocarcinoma and Embryonal Carcinoma

A malignant mixed germ cell tumor that arises from the testis and is characterized by the presence of choriocarcinoma and embryonal carcinoma morphologic components.


Testicular Mixed Choriocarcinoma and Teratoma

A malignant mixed germ cell tumor arising from the testis.  It is characterized by the presence of a teratomatous component and malignant syncytiotrophoblastic cells.


Sensory Disorders

An interruption or alteration in the sensory activity or functions of the nervous system.


Immunotoxicity

Toxicity that impairs or damages the immune system.


FIGO Stage I Gestational Trophoblastic Tumor

Lesion is confined to the uterus.


FIGO Stage II Gestational Trophoblastic Tumor

Lesion invades outside of the uterus, but it is limited to the genital structures.


FIGO Stage III Gestational Trophoblastic Tumor

Lesion affects the lungs, with or without known genital structures invasion.


Recurrent Adrenal Cortical Carcinoma

The reemergence of adrenal cortical carcinoma after a period of remission.


Foregut Neuroendocrine Tumor G1

A neuroendocrine tumor that arises from the esophagus, stomach, or duodenum.


Midgut Neuroendocrine Tumor G1

A neuroendocrine tumor grade 1 that arises from the jejunum, ileum, proximal colon, or appendix.


Hindgut Neuroendocrine Tumor G1

A neuroendocrine tumor that arises from the sigmoid colon, descending colon, or rectum.


Carcinoid tumor of the duodenum

A well differentiated, low grade neuroendocrine neoplasm that arises from the duodenum. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.


Stage III Bone Sarcoma AJCC v7

Stage III includes: T3, N0, M0, G3, G4. T3: Tumor more than 8 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G3: Poorly differentiated.  G4: Undifferentiated. (AJCC 7th ed.)


Plexiform fibrohistiocytic tumor

An intermediate fibrohistiocytic neoplasm of the skin that usually affects children and young adults. It is a multinodular, poorly circumscribed tumor characterized by the presence of multinucleated giant cells, mononuclear histiocyte-like cells, and spindle fibroblast-like cells arranged in a plexiform pattern.


atypical lipomatous tumor

An intermediate, locally aggressive lipomatous neoplasm. Microscopically, the adipose tissue contains large and pleomorphic lipoblasts, and is dissected by fibrous septa containing spindle cells. It requires a wide local excision, may recur locally, but never metastasizes.


Non-small cell carcinoma

A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.


Malignant Pancreatic Insulinoma

An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin. It displays vascular invasion and metastasizes to other anatomic sites.


Glucagonoma, malignant

A glucagon-producing neuroendocrine tumor arising from the alpha cells of the pancreas.  It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia.  It displays vascular invasion and metastasizes to other anatomic sites.


Somatostatinoma, malignant

A neuroendocrine tumor arising from delta cells which produce somatostatin. It displays vascular invasion and metastasizes to other anatomic sites.


Malignant Testicular Sertoli Cell Tumor

A Sertoli cell tumor that arises from the testis and is characterized by nuclear pleomorphism, increased mitotic activity and necrotic changes.  Metastases may be present at diagnosis.


Stage I Soft Tissue Sarcoma AJCC v7

Stage I includes: IA (T1a, N0, M0, G1, GX); (T1b, N0, M0, G1, GX); IB (T2a, N0, M0, G1, GX); (T2b, N0, M0, G1, GX).  T1a: Superficial tumor 5 cm or less in greatest dimension.  T1b: Deep tumor 5 cm or less in greatest dimension.  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Grade 1.  GX: Grade cannot be assessed. (AJCC 7th ed.)


Stage II Soft Tissue Sarcoma AJCC v7

Stage II includes: IIA (T1a, N0, M0, G2, G3); (T1b, N0, M0, G2, G3); IIB (T2a, N0, M0, G2); (T2b, N0, M0, G2).  T1a: Superficial tumor 5 cm or less in greatest dimension.  T1b: Deep tumor 5 cm or less in greatest dimension.  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G2: Grade 2.  G3: Grade 3. (AJCC 7th ed.)


Stage 1 Neuroblastoma

Localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor microscopically. (cancer.gov)


Stage 2 Neuroblastoma

Stage 2 includes stage 2A and stage 2B.  Stage 2A: Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph nodes negative for tumor microscopically. Stage 2B: Localized tumor with or without complete gross excision, with ipsilateral nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically. (cancer.gov)


Stage 3 Neuroblastoma

Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement. The midline is defined as the vertebral column. Tumors originating on one side and crossing the midline must infiltrate to or beyond the opposite side of the vertebral column. (cancer.gov)


Disseminated neuroblastoma

Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs, except as defined for stage 4S. (cancer.gov)


Stage I Pleural Malignant Mesothelioma AJCC v7

Stage I includes: (T1, N0, M0); IA: (T1a, N0, M0); IB: (T1b, N0, M0).  T1: Pleural mesothelioma with a tumor limited to the ipsilateral parietal pleura with or without mediastinal pleura and with or without diaphragmatic pleural involvement. T1a: Pleural mesothelioma with no involvement of the visceral pleura. T1b: Pleural mesothelioma with a tumor also involving the visceral pleura N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage II Pleural Malignant Mesothelioma AJCC v7

Stage II includes: T2, N0, M0.  T2: Pleural mesothelioma with a tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following: involvement of diaphragmatic muscle; extension of tumor from visceral pleura into the underlying pulmonary parenchyma.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Pleural Malignant Mesothelioma AJCC v7

Stage III includes: (T1, T2, N1, M0); (T1, T2, N2, M0); (T3, N0, N1, N2, M0).  T1: Pleural mesothelioma with a tumor limited to the ipsilateral parietal pleura with or without mediastinal pleura and with or without diaphragmatic pleural involvement. T2: Pleural mesothelioma with a tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following: involvement of diaphragmatic muscle; extension of tumor from visceral pleura into the underlying pulmonary parenchyma.  T3: Pleural mesothelioma with a locally advanced but potentially respectable tumor.  Tumor involving all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following: involvement of the endothoracic fascia; extension into the mediastinal fat; solitary, completely respectable focus of tumor extending into the soft tissues of the chest wall; nontransmural involvement of the pericardium.  N0: No regional lymph node metastasis.  N1: Pleural mesothelioma with metastases in the ipsilateral bronchopulmonary or hilar lymph nodes. N2: Pleural mesothelioma with metastases in the subcarinal or the ipsilateral mediastinal lymph nodes including the ipsilateral internal mammary and peridiaphragmatic nodes. M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Pleural Malignant Mesothelioma AJCC v7

Stage IV includes: (T4, Any N, M0); (Any T, N3, M0); (Any T, Any N, M1).  T4: Pleural mesothelioma with a locally advanced technically unresectable tumor.  Tumor involving all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction; direct transdiaphragmatic extension of tumor to the peritoneum; direct extension of tumor to the contralateral pleura; direct extension of tumor to mediastinal organs; direct extension of tumor into the spine; tumor extending through to the internal surface of the pericardium with or without a pericardial effusion or tumor involving the myocardium.  N3: Pleural mesothelioma with metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral supraclavicular lymph nodes.  M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Stage IIIB Lung Large Cell Carcinoma AJCC v7

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIIA Lung Large Cell Carcinoma AJCC v7

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Non-small cell lung cancer stage I

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Clear cell tumor

A purely morphologic term that describes a neoplasm in which all or the majority of the neoplastic cells have a clear cytoplasm, when examined under light microscopy, using the conventional staining method (H-E). This term does not provide any information about the nature of the neoplasm (benign or malignant), cell of origin (e.g. epithelial versus mesenchymal versus hematopoietic), or prognosis. Further examination using special stains and/or immunohistochemistry is required to appropriately classify this tumor.


Stage III Lung Small Cell Carcinoma AJCC v7

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIIA Lung Small Cell Carcinoma AJCC v7


Oligodendroblastoma

An obsolete term referring to neoplasms arising from oligodendrocytes.


Stage IIIB Lung Small Cell Carcinoma AJCC v7


Stage IV Lung Small Cell Carcinoma AJCC v7

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Diffuse Hyperplastic Perilobar Nephroblastomatosis


Stable angina

Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration or oral, sublingual or transdermal antianginal medications.


Stage IV Osteosarcoma AJCC v7

Stage IV includes: IVA (Any T, N0, M1a, Any G); IVB (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G).  N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M1a: Distant metastasis to lung.  M1b: Metastasis to other distant sites. (AJCC 7th ed.)


Stage IVA Osteosarcoma AJCC v7

Stage IVA includes: Any T, N0, M1a, Any G.  N0: No regional lymph node metastasis.  M1a: Distant metastasis to lung. (AJCC 7th ed.)


Stage IVB Osteosarcoma AJCC v7

Stage IVB includes: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G).  N1: Regional lymph node metastasis.  M1b: Metastasis to other distant sites. (AJCC 7th ed.)


Stage IIA Esophageal Adenocarcinoma AJCC v7

Stage IIA includes: T2, N0, M0, G3.  T2: Tumor invades muscularis propria. N0: No regional lymph node metastasis.  M0: No distant metastasis. G3: Poorly differentiated.  (AJCC 7th ed.)


Stage IIB Esophageal Adenocarcinoma AJCC v7

Stage IIB includes: (T3, N0, M0, Any G); (T1-2, N1, M0, Any G).  T3: Tumor invades adventitia. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)


Malignant Pancreatic Somatostatinoma

A neuroendocrine tumor that arises from the delta cells of the pancreas. It is characterized by inappropriate secretion of somatostatin and associated with diabetes mellitus, hypochlorhydria, gallbladder disease, diarrhea, steatorrhea, anemia, and weight loss. It displays vascular invasion and metastasizes to other anatomic sites.


Pancreatic Alpha Cell Adenoma

A benign endocrine neoplasm arising from the alpha cells of the pancreas.  It produces glucagon.


Pancreatic Beta Cell Adenoma

An adenoma arising from the beta cells of the pancreas.  It produces insulin.


Malignant gastrinoma of pancreas

A gastrin-producing neuroendocrine tumor arising from the pancreas.  It is characterized by inappropriate secretion of gastrin and associated with Zollinger Ellison syndrome.  It displays vascular invasion and metastasizes to other anatomic sites.


Pancreatic Delta Cell Adenoma

An endocrine neoplasm arising from the delta cells of the pancreas which produce somatostatin. It does not show evidence of vascular invasion or metastasis to other anatomic sites.


Testicular Mixed Choriocarcinoma and Yolk Sac Tumor

A malignant germ cell tumor arising from the testis.  It is characterized by a mixture of choriocarcinoma and yolk sac tumor morphologic elements.  Patients may present with painless or painful testicular swelling.


Recurrent Sinonasal Carcinoma

The reemergence of nasal cavity or paranasal sinus carcinoma after a period of remission.


Recurrent Childhood Medulloblastoma

The reemergence of childhood medulloblastoma after a period of remission.


Endometrioid carcinoma of prostate

A usually aggressive invasive adenocarcinoma of the prostate gland composed of large glands containing tall columnar cells.  The columnar cells have abundant cytoplasm and are reminiscent of endometrial carcinoma.  This type of adenocarcinoma has a tendency to metastasize to the lung and penis.


Primary Cutaneous B-Cell Non-Hodgkin Lymphoma

A B-cell non-Hodgkin lymphoma arising from the skin.  Representative examples include cutaneous marginal zone B-cell lymphoma and cutaneous follicle center lymphoma.


Oropharyngeal lymphepithelioma

A non-keratinizing carcinoma arising from the oropharynx.  It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate.


Childhood Teratoma

A mature or immature teratoma occurring in children.


Childhood Extracranial Germ Cell Tumor

A childhood benign or malignant germ cell tumor arising from an anatomic site other than the brain.


Childhood Malignant Testicular Germ Cell Tumor

A malignant germ cell tumor in children arising from the testis.  It includes the embryonal carcinoma, yolk sac tumor, choriocarcinoma, and mixed germ cell tumors.


Childhood Malignant Ovarian Germ Cell Tumor

A malignant germ cell tumor in children arising from the ovary.  It includes the dysgerminoma, yolk sac tumor, choriocarcinoma, embryonal carcinoma and immature teratoma.


Childhood Extragonadal Malignant Germ Cell Tumor

A malignant germ cell tumor in children arising from an anatomic site other than the testis or ovary.


Childhood Atypical Teratoid/Rhabdoid Tumor

An atypical teratoid/rhabdoid tumor occurring in children.


Adrenal Cortical Low Grade Carcinoma

A carcinoma that arises from the adrenal cortex and is characterized by the presence of twenty or less mitoses per ten square millimeters.


Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

A B acute lymphoblastic leukemia that occurs during childhood. It is characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.


Marginal zone lymphoma stage I

Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).


Marginal zone lymphoma stage II

Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (PDQ)


Marginal zone lymphoma stage III

Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).


Marginal zone lymphoma stage IV

Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.


Marginal zone lymphoma recurrent

The reemergence of marginal zone lymphoma after a period of remission.


Adult Oligodendroglial Tumor

An oligodendroglial tumor of the central nervous system occurring in adults.


childhood nasal type extranodal NK/T-cell lymphoma

A nasal type extranodal NK/T-cell lymphoma occurring in childhood.


Adult Pure Erythroid Leukemia

A pure erythroid leukemia occurring in adults.


Adult Erythroleukemia

An erythroleukemia occurring in adults.


Adult Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A

An acute myeloid leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A occurring in adults.


Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11

An acute myeloid leukemia with inv(16)(p13.1q22); CBFB-MYH11 occurring in adults.


Adult Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11

An acute myeloid leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 occurring in adults.


Adult Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1

An acute myeloid leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1 occurring in adults.


Adult Gliosarcoma

A gliosarcoma occurring in adults.


Adult Giant Cell Glioblastoma

A giant cell glioblastoma occurring in adults.


Adult Supratentorial Embryonal Tumor, Not Otherwise Specified

A supratentorial embryonal tumor, not otherwise specified that occurs in adults.


Stage IV Anal Canal Cancer AJCC v6 and v7

Stage IV includes: (Any T, Any N, M1).  M1: Distant metastasis. (AJCC 6th and 7th Eds.)


HER2/Neu Positive

A laboratory test result indicating the presence of HER2/Neu in a tissue sample.


HER2/Neu Negative

The absence of detectable HER2/Neu in a tissue sample.


Oligodendroglial Component Present

A tumor component characterized by the presence of a diffuse, homogeneous population of tumor cells (oligodendroglial cells) with round nuclei and clear cytoplasm.  The infiltrate has a honeycomb appearance.  An oligodendroglial component can be seen in central nervous system tumors including glioblastomas and mixed gliomas.


mucinous cystic neoplasm with moderate dysplasia

A non-invasive mucinous cystic neoplasm that arises from the pancreas and is characterized by the presence of moderate dysplasia.  The neoplastic columnar mucin-producing epithelial cells form papillary projections or crypt-like invaginations. There is cellular pseudostratification and mitotic activity present.


HLA-A*0201 Positive Cells Present

A laboratory test result indicating the presence of HLA-A*0201 positive cells in a tissue sample.


Acute Myeloid Leukemia with a Variant KMT2A Rearrangement

A term referring to acute myeloid leukemias with rearrangement of the KMT2A gene that results in translocations with various genes other than the MLLT3 (AF9) gene.


Sclerosis

A pathological hardening or thickening of tissue, especially that of the interstitial substance.


HLA-A2 Positive Cells Present

A laboratory test result indicating the presence of HLA-A*02 positive cells in a tissue sample.


Anaplastic Kidney Wilms Tumor

Wilms tumor of the kidney characterized by the presence of nuclear anaplasia.  Anaplasia is defined by the presence of all of the following: multipolar polyploid mitotic figures, marked nuclear enlargement, and hyperchromasia.  When anaplasia is diffuse, it is associated with an unfavorable clinical outcome.


Central Nervous System Embryonal Neoplasm

A malignant neoplasm of embryonal origin, arising from the central nervous system.  It usually affects children.  Representative examples include ependymoblastoma, medulloblastoma, and atypical teratoid/rhabdoid tumor.


Central Nervous System Hemangioblastoma

A rare, slow-growing, WHO grade I tumor of uncertain histogenesis that arises from the central nervous system. It is composed of stromal cells and abundant capillaries. It can occur sporadically or as part of von Hippel- Lindau syndrome.


Intracranial Myeloid Sarcoma

A myeloid sarcoma that affects the meninges or the cerebral hemispheres.


Plasma cell myeloma refractory

Multiple myeloma that is resistant to treatment.


Plasma cell myeloma recurrent

The reemergence of multiple myeloma after a period of remission.


Mature B-Cell Non-Hodgkin Lymphoma

A non-Hodgkin lymphoma that originates from mature B lymphocytes. Representative examples include diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma.


CD20-Positive Neoplastic Cells Present

An immunophenotypic finding indicating that expression of CD20 has been detected in a sample of neoplastic cells.


Recurrent Adult Diffuse Small Cleaved Cell Lymphoma

The reemergence of adult diffuse small cleaved cell lymphoma after a period of remission.


Partial Response of Multiple Myeloma or Plasma Cell Leukemia

Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.


Progression of Multiple Myeloma or Plasma Cell Leukemia

Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.


ISS Stage I Plasma Cell Myeloma

Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)


ISS Stage II Plasma Cell Myeloma

Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.


ISS Stage III Plasma Cell Myeloma

Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)


Melanoma recurrent

The reemergence of a melanoma after a period of remission.


Recurrent Non-Cutaneous Melanoma

The reemergence of non-cutaneous melanoma after a period of remission.


Metastatic Non-Cutaneous Melanoma

A non-cutaneous melanoma that has spread from its original site of growth to another anatomic site.


Adult Pilocytic Astrocytoma

A pilocytic astrocytoma occurring in adults.


Adult Subependymal Giant Cell Astrocytoma

A subependymal giant cell astrocytoma occurring in adults.


Prolonged QT interval

Increased time between the start of the Q wave and the end of the T wave as measured by the electrocardiogram (EKG).


Non-sustained ventricular tachycardia

An electrocardiographic finding of ventricular tachycardia less than 30 seconds in duration.


Anterior Myocardial Infarction by ECG Finding

An electrocardiographic finding of pathologic Q waves in leads V3 and V4, which is suggestive of myocardial infarction of the anterior wall of the left ventricle. (CDISC)


Wide QRS Tachycardia by ECG Finding

An electrocardiographic finding of three or more consecutive wide QRS complexes of uncertain origin with a rate greater than a certain threshold (100 or 120 beats per minute are commonly used). (CDISC)


Recurrent Liver Carcinoma

The reemergence of liver carcinoma after a period of remission.


Hepatic cancer stage IVA

Stage IVA carcinoma of the liver according to the American Joint Committee on Cancer, 7th and 8th editions.


Stage IVB Liver Cancer

Stage IVB carcinoma of the liver according to the American Joint Committee on Cancer, 7th and 8th editions.


Adult Grade I Meningioma

A grade I meningioma that occurs during adulthood.


Childhood Grade I Meningioma

A grade I meningioma that occurs during childhood.


Childhood Grade II Meningioma

A grade II meningioma that occurs during childhood.


Childhood Grade III Meningioma

A grade III meningioma that occurs during childhood.


Adult Grade II Meningioma

A grade II meningioma that occurs during adulthood.


Adult Grade III Meningioma

A grade III meningioma that occurs during adulthood.


PRETEXT I Hepatoblastoma

An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves only 1 quadrant; 3 adjoining liver quadrants are free of tumor. (from PDQ 2004)


PRETEXT II Hepatoblastoma

An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 2 adjoining quadrants; 2 adjoining quadrants are free of tumor. (from PDQ 2004)


PRETEXT III Hepatoblastoma

An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 3 adjoining quadrants or 2 nonadjoining quadrants; 1 quadrant or 2 nonadjoining quadrants are free of tumor. (from PDQ 2004)


PRETEXT IV Hepatoblastoma

An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves all 4 quadrants; there is no quadrant free of tumor. (from PDQ 2004)


Recurrent Brain Neoplasm

The reemergence of a brain neoplasm after a period of remission.


Recurrent Primary Central Nervous System Neoplasm

The reemergence of a primary central nervous system neoplasm after a period of remission.


Refractory Primary Central Nervous System Neoplasm

A primary central nervous system neoplasm that is resistant to treatment.


Refractory Brain Neoplasm

Brain neoplasm that is resistant to treatment.


Recurrent Childhood Spinal Cord Neoplasm

The reemergence of a spinal cord neoplasm in childhood after a period of remission.


Adult Diffuse Astrocytoma

A low grade (WHO grade II) astrocytoma occurring during adulthood.  It is characterized by a high degree of cellular differentiation, slow growth, and diffuse infiltration of neighboring brain structures.


Smoldering Adult T-Cell Leukemia/Lymphoma

An adult T-cell leukemia/lymphoma characterized by less than 5% neoplastic lymphocytes in the peripheral blood, absence of lymphadenopathy and hypercalcemia, and occasional skin or pulmonary lesions.


Chronic Adult T-Cell Leukemia/Lymphoma

An adult T-cell leukemia/ lymphoma associated with skin lesions and mild lymphadenopathy.  Neoplastic lymphocytes are not numerous in the peripheral blood.  Hypercalcemia is absent.


Polymorphic lymphoproliferative disorder following transplant

A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.


grade 3A follicular lymphoma

A grade 3 follicular lymphoma in which centrocytes are present.


grade 3B follicular lymphoma

A grade 3 follicular lymphoma composed of solid sheets of centroblasts.


Infrequent Neoplasm

A neoplasm that is uncommon.


atypical carcinoid tumor

A carcinoid tumor characterized by a high mitotic rate, often associated with the presence of necrosis and nuclear pleomorphism.


Childhood B Lymphoblastic Lymphoma

A B-lymphoblastic lymphoma that occurs during childhood.


AIDS-Related Diffuse Large B-cell Lymphoma

A diffuse large B-cell lymphoma occurring in HIV-positive patients.


AIDS-Related Diffuse Large Cell Lymphoma

A diffuse large cell lymphoma developing in an HIV positive patient.


Adult T Lymphoblastic Lymphoma

T-lymphoblastic lymphoma occurring in adults.


Refractory T Lymphoblastic Lymphoma

T-lymphoblastic lymphoma that does not respond to treatment.


Refractory Mature B-Cell Non-Hodgkin Lymphoma

Mature B-cell non-Hodgkin lymphoma that does not respond to treatment.


Blastoid Variant Mantle Cell Lymphoma

An aggressive mantle cell lymphoma characterized by the presence of neoplastic B-lymphocytes resembling lymphoblasts.


Monomorphic Post-Transplant Lymphoproliferative Disorder

A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.


Plasmacytic Hyperplasia Post-Transplant Lymphoproliferative Disorder

An early post-transplant lymphoproliferative lesion characterized by plasmacytic proliferation and architectural preservation of the involved tissues.  It often regresses either spontaneously or after reduction in immunosuppression.  The immunoglobulin genes are not rearranged.  In some cases, a polymorphic or monomorphic post-transplant lymphoproliferative disorder may follow this early lesion.


Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed B-lymphocytes or plasma cells. The clonal cellular infiltrates fulfill the criteria for a diffuse large B-cell lymphoma, Burkitt lymphoma, or a plasma cell neoplasm.


Classical Hodgkin lymphoma type posttransplant lymphoproliferative disorder

A lymphoproliferative disorder that fulfills the criteria for classic Hodgkin lymphoma and arises as a result of post-transplant immunosuppression therapy. It is most often seen in renal transplant patients.


CD45-Positive Neoplastic Cells Present

An immunophenotypic finding indicating that expression of CD45 has been detected in a sample of neoplastic cells.


Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma

The reemergence of nodular lymphocyte predominant B-cell lymphoma after a period of remission.


Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

Nodular lymphocyte predominant B-cell lymphoma that is resistant to treatment.


Ovarian Granulosa-Stromal Cell Tumor

A group of sex cord-stromal tumors that arise from the ovary.  These tumors are characterized by the presence of granulosa cells, stromal cells, and/or theca cells.  This group includes granulosa cell tumor and tumors of the thecoma/fibroma group.


Adult Type Ovarian Granulosa Cell Tumor

A low-grade malignant sex cord-stromal tumor that occurs in the ovary and affects middle aged to post-menopausal women. It is composed of granulosa cells in an often fibrothecomatous stroma. The neoplastic cells may form various patterns including the microfollicular, which is characterized by the presence of Call-Exner bodies, macrofollicular, insular, trabecular, and diffuse pattern. Signs and symptoms include abdominal mass, hemoperitoneum, and ascites. Estrogenic and rarely androgenic manifestations may be present. The vast majority of cases present as stage I tumors; however, all tumors have a potential for aggressive clinical course.


Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive

A chronic myeloid leukemia, BCR-ABL1 positive occurring during childhood.


Adult B Lymphoblastic Lymphoma

B-lymphoblastic lymphoma that occurs in adults.


Cervical Squamous Cell Carcinoma In Situ

Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. FIGO no longer includes stage 0. (AJCC 7th ed.)


High Grade Intraepithelial Neoplasia

A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as grade II (moderate dysplasia) or grade III (severe dysplasia).


Mechanical ventilation complication

A disease or condition arising from the use of mechanical ventilation.


A nasopharyngeal carcinoma characterized by the lack of keratinization and the presence of a dense lymphoplasmacytic infiltrate.  It is subdivided into undifferentiated and differentiated types, based on the cytologic features of the malignant cells.  The undifferentiated type is characterized by the presence of cells with large vesicular nuclei with prominent nucleoli and a syncytial pattern of growth.  The differentiated type is characterized by the presence of smaller cells and cellular stratification reminiscent of transitional cell carcinoma.  While morphologically distinct, both types have similar clinical presentation and prognosis.


EBV-Positive Neoplastic Cells Present

An immunophenotypic finding indicating that Epstein-Barr virus has been detected in a sample of neoplastic cells.


Pulmonary Precancerous Condition

A premalignant pathologic process that affects the lungs.  This category includes bronchial intraepithelial neoplasia and atypical adenomatous hyperplasia.


Bone Marrow Suppression

A condition in which the production of red blood cells, white blood cells, and/or platelets by bone marrow stem cells is inhibited, usually as a side effect of treatment with various anti-cancer agents, radiation, or tumor development within the bone marrow.


Normal Skin

The pores are visible but not large. The skin texture is neither fine or thick and it neither feels dry or oily to the touch.


Acute Erythroid Leukemia in Remission

A finding of acute erythroid leukemia that is not growing and responds to treatment.


Recurrent Urethral Cancer

The reemergence of urethral carcinoma after a period of remission


Stage II Renal Pelvis and Ureter Cancer AJCC v7

Stage II includes: T2, N0, M0.  T2: Tumor invades the muscularis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Renal Pelvis and Ureter Cancer AJCC v7

Stage III includes: T3, N0, M0. T3: For renal pelvis only: tumor invades beyond muscularis into peripelvic fat or the renal parenchyma.  For ureter only: tumor invades beyond muscularis into periureteric fat.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Recurrent Childhood Visual Pathway Glioma

The reemergence of visual pathway glioma in childhood after a period of remission.


Graft failure

Failure of transplanted tissue to become functional or operational, often as a result of destruction by the host's immune system.


Stage IV Vaginal Cancer AJCC v6 and v7

Stage IV includes: IVA: (T4, Any N, M0) and IVB: (Any T, Any N, M1).  T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify tumor as T4).  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 6th and 7th eds.)


Partial thickness burn

An injury that includes the entire epidermis and upper layers of the dermis due to a chemical, friction, radiation or thermal exposure. The affected area appears as moist red or white skin that does not blanch. Often it is painful with the presence of blisters.


Full thickness burn

An injury that includes all skin layers into the subcutaneous tissue due to chemical, friction, radiation or thermal exposure. The affected area appears dry and thickened; damage to nerve endings usually renders the wound painless.


Adult Diffuse Large B-Cell Lymphoma

A diffuse large B-cell lymphoma occurring in adults.


Childhood Diffuse Large B-Cell Lymphoma

A diffuse large B-cell lymphoma that occurs during childhood.


Recurrent Carcinoma

The reemergence of a carcinoma after a period of remission.


Recurrent Female Reproductive System Carcinoma

The reemergence of female reproductive system carcinoma after a period of remission.


Recurrent Male Reproductive System Carcinoma

The reemergence of a carcinoma that affects the male reproductive system after a period of remission.


Recurrent Digestive System Carcinoma

The reemergence of carcinoma in any part of the digestive system after a period of remission.


Recurrent Head and Neck Carcinoma

The reemergence of carcinoma in the head and neck region after a period of remission.


Pancreatic carcinoma recurrent

The reemergence of pancreatic carcinoma after a period of remission.


Refractory Neoplasm

A neoplasm that does not respond to treatment.


Metastatic Breast Lobular Carcinoma

A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Localized Gallbladder Carcinoma

A carcinoma that arises from the gallbladder and it has not spread to other anatomic sites.


High Grade Cervical Intraepithelial Neoplasia

Squamous or glandular cervical intraepithelial neoplasia characterized by the presence of moderate or severe dysplastic changes.


mixed lobular and ductal breast carcinoma

A breast carcinoma characterized by the presence of a lobular and a ductal component. The ductal component comprises less than 50 percent of the tumor.


Carcinoma liver resectable

A hepatocellular carcinoma that is amenable to surgical resection.


Inflammatory carcinoma of breast stage IV

An inflammatory carcinoma of the breast that has spread to other anatomic sites.


Nicotine withdrawal

A condition which occurs following suspension of nicotine use. Clinical features may include nicotine craving, irritability, anxiety, depression and increased appetite. The onset of symptoms may be rapid with severity proportional to length and amount of nicotine use. Unsuccessful management of symptoms may prompt a return to nicotine use.


Adult Hodgkin Lymphoma

Hodgkin lymphoma occurring in adults.


Childhood Brain Neoplasm

A benign or malignant, primary or metastatic neoplasm of the brain occurring in children.


Adult Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma occurring in adults.


Childhood Rhabdomyosarcoma

An aggressive malignant mesenchymal neoplasm arising from skeletal muscle in children.  Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.


Childhood Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma occurring in childhood.


Adult Soft Tissue Sarcoma

Soft tissue sarcoma occurring in adults.


Childhood Malignant Liver Neoplasm

A malignant neoplasm that affects the liver and occurs during childhood.


Gastrointestinal Carcinoid Tumor

A well differentiated neuroendocrine neoplasm of low grade arising from the digestive system. It is composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with small vesicular nuclei. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent. The tumor can occur anywhere in the digestive system; approximately 90% arise in the appendix.


Neck Squamous Cell Carcinoma of Unknown Primary

A squamous cell carcinoma that has metastasized to the neck lymph nodes from an unknown primary anatomic site.


Childhood Hodgkin Lymphoma

Hodgkin lymphoma occurring in childhood.


Childhood Soft Tissue Sarcoma

Soft tissue sarcoma occurring in childhood.


Malignant pericardial effusion

Presence of fluid in the pericardial space as a complication of malignant disease.


Stage II Breast Cancer AJCC v6 and v7

Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Stage III Breast Cancer AJCC v6

Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Stage IIIA Breast Carcinoma

Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Breast cancer recurrent

The reemergence of carcinoma in the breast after a period of remission.


Non-small cell lung cancer stage II

Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Non-small cell lung cancer stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Metastatic osteosarcoma

An osteosarcoma which has spread to another anatomical site.


Stage IIIB Breast Carcinoma

Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


Non-small cell lung cancer recurrent

The re-emergence of non-small cell lung carcinoma after a period of remission.


Recurrent Childhood Acute Lymphoblastic Leukemia

The reemergence of acute lymphoblastic leukemia in childhood after a period of remission.


Stage I Pancreatic Cancer AJCC v6 and v7

Stage I includes: IA (T1, N0, M0); IB (T2, N0, M0).  T1: Tumor limited to the pancreas 2 cm or less in greatest dimension.  T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th Eds.)


Stage II Pancreatic Cancer AJCC v6 and v7

Stage II includes: IIA (T3, N0, M0); IIB (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor limited to the pancreas 2 cm or less in greatest dimension.  T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery.  N0: No regional lymph node metastasis. N1: Regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Stage III Pancreatic Cancer AJCC v6 and v7

Stage III includes: T4, Any N, M0. T4: Tumor involves the celiac axis or the superior mesenteric artery.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Recurrent Adult Hodgkin Lymphoma

The reemergence of Hodgkin lymphoma in adulthood after a period of remission.


Stage I Rectal Cancer AJCC v6 and v7

Stage I includes: (T1, N0, M0); (T2, N0, M0).  T1: Tumor invades submucosa.  T2: Tumor invades muscularis propria.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Anal cancer recurrent

The reemergence of anal carcinoma after a period of remission.


Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma


Cervix carcinoma recurrent

The reemergence of cervical carcinoma after a period of remission.


Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

The reemergence of primary cutaneous T-cell non-Hodgkin lymphoma after a period of remission.


Metastatic Ewing's Sarcoma

Ewing sarcoma that has spread from its original site of growth to another anatomic site.


Ewing's sarcoma recurrent

Ewing sarcoma which has recurred after treatment and/or remission. While initial complete responses are not uncommon, there is a fair chance of relapse as late as one to two decades after initial therapy.


Adult Leiomyosarcoma

An aggressive malignant smooth muscle neoplasm, occurring in adults.  It is characterized by a proliferation of neoplastic spindle cells.


Recurrent Childhood Rhabdomyosarcoma

The reemergence of childhood rhabdomyosarcoma after a period of remission.


Childhood Craniopharyngioma

A craniopharyngioma that occurs during childhood.  The vast majority of cases are adamantinomatous craniopharyngiomas.  Clinical signs and symptoms include endocrine deficiencies and visual disturbances.


Anal infection

An infectious process affecting the anal area.


Adult Synovial Sarcoma

A synovial sarcoma occurring in adults.


Stage I Adult Soft Tissue Sarcoma AJCC v7

Stage I includes: IA (T1a, N0, M0, G1, GX); (T1b, N0, M0, G1, GX); IB (T2a, N0, M0, G1, GX); (T2b, N0, M0, G1, GX).  T1a: Superficial tumor 5 cm or less in greatest dimension.  T1b: Deep tumor 5 cm or less in greatest dimension.  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Grade 1.  GX: Grade cannot be assessed. (AJCC 7th ed.)


Stage II Adult Soft Tissue Sarcoma AJCC v7

Stage II includes: IIA (T1a, N0, M0, G2, G3); (T1b, N0, M0, G2, G3); IIB (T2a, N0, M0, G2); (T2b, N0, M0, G2).  T1a: Superficial tumor 5 cm or less in greatest dimension.  T1b: Deep tumor 5 cm or less in greatest dimension.  T2a: Superficial tumor more than 5 cm in greatest dimension.  T2b: Deep tumor more than 5 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G2: Grade 2.  G3: Grade 3. (AJCC 7th ed.)


Stage III Adult Soft Tissue Sarcoma AJCC v7


Stage IV Adult Soft Tissue Sarcoma AJCC v7

Stage IV includes: Any T, Any N, M1, Any G.  M1: Distant metastasis. (AJCC 7th ed.)


Recurrent Adult Soft Tissue Sarcoma

A soft tissue sarcoma occurring in adults that has recurred after a period of remission.


Stage I Renal Cell Carcinoma

Stage I includes: T1, N0, M0.  T1: Lesions have been divided into T1a and T1b.  T1a is defined as tumor 4 cm or less in greatest dimension, limited to the kidney.  T1b is defined as tumor greater than 4 cm but not more than 7 cm in greatest dimension, limited to the kidney.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Renal cell carcinoma recurrent

A reemergence of renal cell carcinoma after a period of remission.


Recurrent Parathyroid Gland Carcinoma

The reemergence of parathyroid gland carcinoma after a period of remission.


Stage I Ovarian Cancer AJCC v6 and v7

Stage I includes: T1, N0, M0. T1: Tumor limited to ovaries (one or both).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Adipose Tissue Atrophy

Shrinking of adipose tissue.


Ovarian epithelial cancer stage II

Stage II includes: T2, N0, M0.  T2: Tumor involves one or both ovaries with pelvic extension and/or implants.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Flu-Like Symptoms

Complaints describing a pattern similar to influenza, which may include one or more of the following symptoms: fever, chills, muscle or body aches, cough, sore throat, rhinitis, or fatigue.


Ovarian cancer stage III

Stage III includes: T3, N0, M0.  T3: Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Digestive System Fistula

An abnormal communication between any part of the digestive system and another organ or cavity.


Stage IV Ovarian Cancer AJCC v6 and v7

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 6th and 7th eds.)


Recurrent ovarian cancer

The reemergence of ovarian carcinoma after a period of remission.


Recurrent Childhood Brain Neoplasm

The reemergence of brain neoplasm in childhood after a period of remission.


Localized Resectable Neuroblastoma

Neuroblastoma that is confined to a specific site and is amenable to surgical removal.


Infection and inflammatory reaction due to internal orthopedic fixation device

An infectious process involving an implanted medical device and the surrounding tissues.


Regional Neuroblastoma

A neuroblastoma confined to a specific anatomic region without evidence of dissemination.


Neuroblastoma recurrent

The reemergence of neuroblastoma after a period of remission.


Stage IV Childhood Hepatocellular Carcinoma AJCC v7

Stage IV includes: IVA: (Any T, N1, M0); IVB: (Any T, Any N, M1). N1: Regional lymph node metastasis. M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)


Recurrent Childhood Liver Cancer

A malignant neoplasm of the liver that occurs during childhood and has recurred after a period of remission.


Stage I Kidney Wilms Tumor

Wilms tumor that is found in one kidney and can be completely removed with surgery. (National Wilms Tumor Study Group Staging System)


Stage II Kidney Wilms Tumor

Wilms tumor that is found in the kidney and in the fat, soft tissue, or blood vessels near the kidney. It may have spread to the renal sinus. The renal sinus is the part of the kidney where blood and fluid enter and exit the organ. The tumor can be completely removed with surgery. (National Wilms Tumor Study Group Staging System)


Stage III Kidney Wilms Tumor

Wilms tumor that is found in areas near the kidney and cannot be completely removed with surgery. The tumor may have spread to nearby organs and blood vessels or throughout the abdomen and to nearby lymph nodes. Lymph nodes are tiny, bean-shaped organs that help fight infection. Stage III cancer has not spread outside the abdomen. (National Wilms Tumor Study Group Staging System)


Stage IV Kidney Wilms Tumor

Wilms tumor that has spread to other more distant organs, such as the lungs, liver, bones, and brain, or to lymph nodes outside the abdomen (National Wilms Tumor Study Group Staging System)


Stage V Kidney Wilms Tumor

Wilms tumor that affects both kidneys at the same time. The tumor in each kidney is staged separately (National Wilms Tumor Study Group Staging System)


Recurrent Kidney Wilms Tumor

The reemergence of Wilms tumor of the kidney after a period of remission.


Chronic lymphocytic leukemia stage 0

Risk: Low; Findings: Lymphocytosis only; Survival (months): more than 120. (from AJCC 8th Ed.)


Recurrent Retinoblastoma

The reemergence of retinoblastoma after a period of remission.


DS Stage I Plasma Cell Myeloma

Multiple myeloma with all of the following: 1. Hemoglobin greater than 10 g/Dl, 2. Normal serum calcium, 3. Normal bone structure, 4. Low monoclonal (or myeloma) protein (M protein) production as shown by: a. IgG less than 5.0 g/dL, b. IgA less than 3.0 g/dL, c. Urinary kappa or lamda less than 4 g/24 hours. Estimated myeloma cell mass: less than 0.6 trillion (1012)/m2 (low burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL. Impaired renal function worsens prognosis regardless of stage. Note that the newer International Staging System defines stage I quite differently: Beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months). (PDQ)


DS Stage II Plasma Cell Myeloma

Multiple myeloma that fits in neither stage I nor stage III.  Estimated myeloma cell mass: 0.6 to 1.2 trillion (1012)/m2 (intermediate burden).  The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL.  Impaired renal function worsens prognosis regardless of stage.  Note that the newer International Staging System defines stage II quite differently: Beta-2-microglobulin less than 3.5 and albumin less than 3.5 or beta-2-microglobulin 3.5 to less than 5.5 (median survival of 44 months).  (PDQ)


DS Stage III Plasma Cell Myeloma

Multiple myeloma with one or more of the following: 1. Hemoglobin less than 8.5 g/dL. 2. Serum calcium greater than 12.0 mg/dL. 3. More than three lytic bone lesions. 4. High M protein production as shown by: a. IgG greater than 7.0 g/dL. b. IgA greater than 5.0 g/dL. c. Urinary kappa or lamda greater than 12.0 g/24 hours. Estimated myeloma cell mass: greater than 1.2 trillion (1012)/m2 (high burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL. b. Creatinine greater than or equal to 2.0 mg/dL. Serum beta-2-microglobulin has been shown to be a reliable marker for prognosis. Since the great majority of symptomatic myeloma patients are classified as stage III by the Durie/Salmon criteria, this staging system has not proven to be very useful for identifying the patients with intermediate and poor prognosis. Note that the newer International Staging System defines stage III quite differently: Beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months). (PDQ)


Small cell lung cancer limited stage

Small cell lung carcinoma which is confined to one hemi-thorax and the regional lymph nodes.


Stage I Vaginal Cancer AJCC v6 and v7

Stage I includes: (T1, N0, M0).  T1: Tumor confined to vagina.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage II Vaginal Cancer AJCC v6 and v7

Stage II includes: T2, N0, M0. T2: Tumor invades paravaginal tissues but not to pelvic wall.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage III Vaginal Cancer AJCC v6 and v7

Stage III includes: (T1-3, N1, M0) and (T3, N0, M0). T1: Tumor confined to vagina.  T2: Tumor invades paravaginal tissues but not to pelvic wall.  T3: Tumor extends to pelvic wall.  N0: No regional lymph node metastasis.  N1: Pelvic or inguinal lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IVA Vaginal Cancer AJCC v6 and v7

Stage IVA includes: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4).  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Vaginal cancer recurrent

The reemergence of vaginal carcinoma after a period of remission.


Regional Digestive System Neuroendocrine Tumor G1

Digestive system neuroendocrine tumor G1 that has not spread to other regions.


Recurrent Digestive System Neuroendocrine Tumor G1

The reemergence of digestive system neuroendocrine tumor G1 after a period of remission.


Mesothelioma malignant recurrent

The reemergence of malignant mesothelioma after a period of remission


Penis carcinoma recurrent

A carcinoma of the penis that reappears after a period of remission.


Adult Diffuse Mixed Cell Lymphoma

A B-or T-cell non-Hodgkin lymphoma composed of a mixed-sized lymphocytic population occurring in adults.


Wound Complication

A medical condition that develops at the site of an existing wound. Examples include swelling, draining, bleeding, formation of hematoma, infection, and necrosis.


Adult Diffuse Large Cell Lymphoma

A B-or T-cell non-Hodgkin lymphoma composed of a diffuse large cell lymphocytic infiltrate occurring in adults.


Adult Immunoblastic Lymphoma

A morphologic variant of diffuse large B-cell lymphoma occurring in adults.  It is characterized by the presence of large lymphoid cells with abundant cytoplasm and prominent nucleoli.


Chronic lymphocytic leukemia stage 1

Risk: Intermediate; Findings: Lymphocytosis and adenopathy; Survival (months): 95. (from AJCC 8th Ed.)


Chronic lymphocytic leukemia stage 2

Risk: Intermediate; Findings: Lymphocytosis, adenopathy, and enlarged spleen and/or liver; Survival (months): 72. (from AJCC 8th Ed.)


Chronic lymphocytic leukemia stage 3

Risk: High; Findings: Lymphocytosis and hemoglobin less than 11 g/dL; Survival (months): 30. (from AJCC 8th Ed.)


Localized Resectable Adult Liver Carcinoma

A localized hepatocellular carcinoma or intrahepatic cholangiocarcinoma that occurs during adulthood and it is amenable to surgical resection.


Localized Non-Resectable Adult Liver Carcinoma

A localized hepatocellular carcinoma or intrahepatic cholangiocarcinoma that occurs during adulthood and it is not amenable to surgical resection.


Recurrent Adult Liver Carcinoma

A hepatocellular carcinoma or intrahepatic cholangiocarcinoma that occurs during adulthood and has recurred after a period of remission.


Osteosarcoma recurrent

The reemergence of osteosarcoma after a period of remission.


recurrent adult acute myeloid leukemia

The reemergence of acute myeloid leukemia in adults after a period of remission.


Recurrent Adult Acute Lymphoblastic Leukemia

The reemergence of acute lymphoblastic leukemia in adults after a period of remission.


Recurrent Adult Brain Neoplasm

The reemergence of brain neoplasm in adulthood after a period of remission.


Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Chronic myeloid leukemia, BCR-ABL1 positive that is resistant to treatment.


Chronic lymphocytic leukemia refractory

Chronic lymphocytic leukemia that is resistant to treatment.


Unresectable Gallbladder Carcinoma

A carcinoma that arises from the gallbladder and it is not amenable to surgical resection.


Localized Extrahepatic Bile Duct Carcinoma

A carcinoma that arises from the extrahepatic bile ducts and it has not spread to other anatomic sites.


Unresectable Extrahepatic Bile Duct Carcinoma

Extrahepatic bile duct carcinoma that is not amenable to surgical removal.


Recurrent Extrahepatic Bile Duct Carcinoma

The reemergence of an extrahepatic bile duct carcinoma after a period of remission.


Small intestine carcinoma recurrent

The reemergence of small intestine carcinoma after a period of remission.


Stage 0 Bladder Carcinoma

Stage 0 includes: 0a (Ta, N0, M0); 0is (Tis, N0, M0).  Ta: Noninvasive papillary carcinoma. Tis: Carcinoma in situ: "flat tumor".  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Stage I Carcinoma of Bladder

Stage I includes: T1, N0, M0.  T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Stage II Bladder Cancer AJCC v6 and v7

Stage II includes: (T2a, N0, M0); (T2b, N0, M0).  T2a: Tumor invades superficial muscle (inner half).  T2b: Tumor invades deep muscle (outer half).  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


Stage III Bladder Cancer AJCC v6 and v7

Stage III includes: (T3a, N0, M0); (T3b, N0, M0); (T4a, N0, M0).  T3a: Tumor microscopically invades perivesical tissue.  T3b: Tumor macroscopically invades perivesical tissue (extravesical mass).  T4a: Tumor invades prostatic stroma, uterus, vagina.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)


Bladder cancer recurrent

The reemergence of bladder carcinoma after a period of remission.


Prostate cancer recurrent

Prostate carcinoma reemerging after a period of remission.


Recurrent Skin Carcinoma

A carcinoma of the skin that has recurred after a period of remission.


Recurrent Thyroid Carcinoma

The reemergence of thyroid gland carcinoma after a period of remission.


Recurrent Uveal Melanoma

The reemergence of uveal melanoma after a period of remission.


Stage I Cutaneous Melanoma AJCC v6

Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0); (T2a, N0, M0).  T1a: Melanoma is less than or equal to 1.0mm in thickness with or without ulceration.  T1b: Melanoma is less than or equal to 1.0mm in thickness and level IV or V with ulceration. T2a: Melanoma 1.01-2.0 mm in thickness, no ulceration.  N0: No regional lymph node metastasis.  M0: No distant metastasis.-2003


Stage II Cutaneous Melanoma AJCC v6 and v7

Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0).  T2b: Cutaneous melanoma with a tumor measuring 1.01-2.0 mm in thickness, with ulceration.  T3a: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, without ulceration.  T3b: Cutaneous melanoma with a tumor measuring 2.01-4.0 mm in thickness, with ulceration.  T4a: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, without ulceration.  T4b: Cutaneous melanoma with a tumor measuring more than 4.0 mm in thickness, with ulceration.  N0: No regional lymph node metastases.  M0: No detectable evidence of distant metastases. (from AJCC 6th and 7th Eds.)


Stage III Cutaneous Melanoma AJCC v6

Stage III includes: (Any T, N1, M0); (Any T, N2, M0); (Any T, N3, M0).  N1: Metastasis in one lymph node.  N2: Metastasis in two to three regional lymph nodes or intralymphatic regional metastasis without nodal metastases.  N3: Metastasis in four or more regional nodes, or matted metastatic nodes, or in-transit metastasis or satellite(s) with metastasis in regional node(s).


Recurrent Salivary Gland Cancer

The reemergence of salivary gland carcinoma after a period of remission.


Recurrent Lymphomatoid Granulomatosis

The reemergence of lymphomatoid granulomatosis after a period of remission.


Recurrent Kaposi Sarcoma

The reemergence of Kaposi sarcoma after a period of remission.


Adult Acute Myeloid Leukemia in Remission

A finding of acute myeloid leukemia in adults that is not growing and responds to treatment.


Adult Acute Lymphoblastic Leukemia in Remission

A finding of acute lymphoblastic leukemia in adults that is not growing and responds to treatment.


Childhood Acute Lymphoblastic Leukemia in Remission

A finding of acute lymphoblastic leukemia in children that is not growing and responds to treatment.


Paget's disease and infiltrating duct carcinoma of breast

Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Childhood Burkitt Leukemia

The leukemic counterpart of Burkitt lymphoma occurring in children.  The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood.  This is an aggressive leukemia.


Diastolic dysfunction

Impairment in the filling of the ventricles during diastole. Causes include hypertrophic and restrictive cardiomyopathies, coronary artery disease, chronic high blood pressure, aortic stenosis, and aging.


Childhood Embryonal Rhabdomyosarcoma

A poorly circumscribed morphologic variant of rhabdomyosarcoma occurring in children.  The neoplasm is characterized by the presence of primitive skeletal muscle in any stage of myogenesis.


Childhood Rhabdomyosarcoma with Mixed Embryonal and Alveolar Features

A mixed rhabdomyosarcoma that occurs in children. The neoplasm is composed of embryonic and alveolar components.  It is characterized by the presence of spindle cells with myoblastic differentiation and a myxoid and a fibrous stroma.


Adult Acute Myeloid Leukemia with Maturation

An acute myeloid leukemia with maturation occurring in adults.


Adult Acute Myelomonocytic Leukemia

An acute myelomonocytic leukemia occurring in adults.


Adult Acute Eosinophilic Leukemia

An acute eosinophilic leukemia occurring in adults.


Adult Acute Basophilic Leukemia

An acute basophilic leukemia occurring in adults.


Adult Acute Megakaryoblastic Leukemia

An acute megakaryoblastic leukemia occurring in adults.


Childhood Acute Promyelocytic Leukemia with PML-RARA

An acute promyelocytic leukemia with PML-RARA fusion occurring in children.


Childhood Acute Myelomonocytic Leukemia

An acute myelomonocytic leukemia occurring in children.


Childhood Acute Basophilic Leukemia

An acute basophilic leukemia occurring in children.


childhood acute megakaryoblastic leukemia

An acute megakaryocytic leukemia that is characterized by fusion oncogenes involving transcriptional regulators in childhood.


Distal Bile Duct Adenocarcinoma

An adenocarcinoma that arises from the common bile duct distal to the insertion of the cystic duct.